GSK To Acquire Bio/Pharma Company Bellus Health for $2 Bn

GlaxoSmithKline (GSK) has agreed to acquire Bellus Health, a Laval, Quebec, Canada-based, bio/pharmaceutical company, for $2 billion.  

Bellus’ lead drug candidate is camlipixant, in Phase III development, for the first-line treatment of adult patients with refractory chronic cough, defined as a cough that persists for more than eight weeks despite optimal treatment of any underlying conditions or where there is no identifiable underlying cause. 

The deal is subject to customary conditions, including court approval, the approval of the acquisition by at least 66.67% of Bellus’ shareholders and a majority of non-interested shareholders at a designated meeting to approve the transaction, and appropriate regulatory agencies.  The transaction is expected to close in the third quarter of 2023 or earlier.  

Source: GlaxoSmithKline and Bellus Health